C WorldWide Group Holding A S lessened its stake in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 7.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 65,600 shares of the specialty pharmaceutical company’s stock after selling 5,543 shares during the period. C WorldWide Group Holding A S’s holdings in Supernus Pharmaceuticals were worth $2,614,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in SUPN. Northern Trust Corp boosted its stake in Supernus Pharmaceuticals by 2.8% in the second quarter. Northern Trust Corp now owns 653,262 shares of the specialty pharmaceutical company’s stock valued at $28,155,000 after acquiring an additional 17,836 shares in the last quarter. Vanguard Group Inc. boosted its stake in Supernus Pharmaceuticals by 39.1% in the second quarter. Vanguard Group Inc. now owns 3,500,535 shares of the specialty pharmaceutical company’s stock valued at $150,873,000 after acquiring an additional 984,200 shares in the last quarter. M&T Bank Corp acquired a new position in Supernus Pharmaceuticals in the second quarter valued at $213,000. Advisor Group Inc. boosted its stake in Supernus Pharmaceuticals by 13.7% in the second quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock valued at $145,000 after acquiring an additional 410 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Supernus Pharmaceuticals by 10.6% in the second quarter. Dimensional Fund Advisors LP now owns 1,268,082 shares of the specialty pharmaceutical company’s stock valued at $54,654,000 after acquiring an additional 122,042 shares in the last quarter. Institutional investors own 98.71% of the company’s stock.

Shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) opened at $37.20 on Friday. Supernus Pharmaceuticals Inc has a 12 month low of $24.65 and a 12 month high of $50.04. The firm has a market cap of $1,904.39, a PE ratio of 35.09 and a beta of 1.08.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. The business had revenue of $80.40 million during the quarter, compared to the consensus estimate of $78.74 million. The company’s revenue for the quarter was up 41.5% compared to the same quarter last year. research analysts expect that Supernus Pharmaceuticals Inc will post 1.07 earnings per share for the current fiscal year.

Several research firms have issued reports on SUPN. B. Riley restated a “buy” rating and issued a $54.00 price objective on shares of Supernus Pharmaceuticals in a research note on Thursday, January 18th. BidaskClub upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 11th. Zacks Investment Research downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, January 12th. SunTrust Banks reiterated a “buy” rating and set a $61.00 target price on shares of Supernus Pharmaceuticals in a research note on Friday, November 3rd. Finally, Cowen set a $50.00 target price on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, October 23rd. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $51.36.

In related news, VP Victor Vaughn sold 55,000 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $40.11, for a total value of $2,206,050.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Padmanabh P. Bhatt sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $44.98, for a total transaction of $899,600.00. Following the completion of the sale, the vice president now owns 32,500 shares of the company’s stock, valued at approximately $1,461,850. The disclosure for this sale can be found here. Insiders have sold 165,750 shares of company stock valued at $7,133,973 in the last quarter. Insiders own 6.70% of the company’s stock.

WARNING: This news story was first posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another domain, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The legal version of this news story can be viewed at https://www.dailypolitical.com/2018/02/11/supernus-pharmaceuticals-inc-supn-position-reduced-by-c-worldwide-group-holding-a-s.html.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals Inc (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.